RxDoctor Payments Data

Marcelina Gomez Almazan, APRN

Family · Loveland, OHNPI 1407454283

Payments from drug & device makers

$1,193in general payments, 2019–2025

Across 59 payments — averaging $20.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$269
  • Lilly USA, LLC$258
  • AstraZeneca$173
  • Merck$91
  • Insulet Corporation$76
  • Exact Sciences$73
  • plus $253 from 9 others

What the payments were for

  • Food & beverage$1,193100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,193 in reported general payments places this provider in the 70th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Medicare billing

Part B allowed, 2024
$420
Medicare patients
11
Services billed
15

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin23$24,522
OzempicSemaglutide21$19,759
FarxigaDapagliflozin Propanediol30$17,823
JanuviaSitagliptin Phosphate17$13,740
XareltoRivaroxaban16$13,212
EliquisApixaban14$9,503
Lantus SolostarInsulin Glargine,hum.Rec.Anlog20$4,252
Albuterol Sulfate HfaAlbuterol Sulfate59$1,317
Duloxetine Hcl89$1,315
Atorvastatin Calcium219$1,163
Levothyroxine Sodium87$968
Gabapentin90$918
Lisinopril144$655
Aripiprazole12$649
Fluticasone Propionate74$553

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$29$24,52223 claims
Novo NordiskOzempic$269$19,75921 claims
AstraZenecaFarxiga$173$17,82330 claims
MerckJanuvia$91$13,74017 claims
PfizerEliquis$40$9,50314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 6,812 family providers in Ohio.

Other family in Loveland

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →